CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
And the winner of Startup Battlefield at Disrupt 2026 is: Intero Biosystems

From TechCrunch

By Sean O'Kane

October 15, 2026

And the winner of Startup Battlefield at Disrupt 2026 is: Intero Biosystems

And the winner of Startup Battlefield at Disrupt 2026 is: Intero Biosystems

For three days this week in San Francisco, 20 eager startups participated in the Startup Battlefield at TechCrunch Disrupt 2026. The top 20 were chosen to represent the best of the Startup Battlefield 200, and they competed for a chance to take home the Startup Battlefield Cup and $100,000. With that intense pitching now complete, we have a winner.

These startups were handpicked to compete in Startup Battlefield, and all of them presented a live demo in front of the VCs and tech leaders who judged the competition.

After hours of deliberations, TechCrunch editors pored over the judges’ notes and narrowed the list down to five finalists: Apate, Flox Intelligence, Intero Biosystems, Industrial Next, and Satlyt.

The final five made their way to the finale to demo in front of our final panel of judges: Alexa von Tobel of Inspired Capital, Chi-Hua Chien of Goodwater Capital, Dayna Grayson of Construct Capital, Karl Alomar of M13, and Stacy Brown-Philpot of Cherryrock Capital.

We’re now ready to announce that the winner of TechCrunch Startup Battlefield 2026 is:

Winner: Intero Biosystems

Intero Biosystems is a Denver-based startup founded by Charlie Childs and Madeline Eiken that spun out of the University of Michigan. It’s developing 1mm human intestinal “organoids,” lab-grown tissue that mimics the gut, offering another way to study how drugs and other compounds might affect the human body before they are tested in people. The startup sells its flagship product, GastroScreen, to pharmaceutical, biotech, food, and chemical companies for testing drugs and other compounds.

Read more about Intero Biosystems in our separate post here.

Runner-up: Apate

Apate is an Australian startup founded by Dali Kaafar, who came up with the idea while doing research at Macquarie University in Sydney, Australia. It deploys thousands of AI agents that masquerade as innocent victims, answering scam calls, responding to shady messages and emails, following phishing links, and joining social media groups to bait fraudsters. In addition to access to Apate’s fleet of agents, customers get an insights portal that offers intelligence and analytics on scams targeting their end users or employees, brands, products, and more.

Read more about Apate in our separate post here.

These two companies now join the ranks of Startup Battlefield winners and finalists like Trello, Discord, Cloudflare, and Mint on the Disrupt Stage. With more than 1,700 alumni having participated in the program, Startup Battlefield Alumni have collectively raised over $30 billion in funding with more than 200 successful exits.

View original article on techcrunch.com

Most Recent

When it came to Cal AI’s viral success, a small army of influencers paid off

The company generated over $30 million in revenue in two years and was acquired by MyFitnessPal for an undisclosed amount of money in March.

Oct 15, 2026

Ricursive Intelligence is betting on AI-designed chips to help solve the compute crisis

The founders detailed how their startup is developing AI that can design chips, learn from each iteration, and improve subsequent designs, all with the goal of automating and accelerating the chip design process.

Oct 14, 2026

Gudea leverages AI to help organizations prevent social media crises before they erupt

Gudea, a company that tracks how stories and rumors spread online that describes itself as the “storm tracker for the internet,” is using AI to help organizations spot trouble brewing online before it turns into a crisis.

Oct 14, 2026

Intero Biosystems wants drugmakers to test on mini human intestines, not animals

Intero Biosystems is selling lab-grown human intestines to drugmakers as regulators push for alternatives to animal testing, while the startup looks to scale production and expand its organoid technology.

Oct 14, 2026

Similar Posts

And the winner of Startup Battlefield at Disrupt 2024 is . . . Salva Health

Over the last three days, 20 startups participated in the incredibly competitive Startup Battlefield at TechCrunch Disrupt. These 20 companies were selected as the best of the Startup Battlefield 200 and competed for a chance to take home the Startup Battlefield Cup and $100,000. After three days of intense pitching, we have a winner. The startups taking part in the Startup Battlefield had all been hand-picked to participate in our startup competition. All the companies presented a live demo in

Oct 30, 2024

How to make the Startup Battlefield Top 20 — and what every company gets regardless

Every founder who applies to Startup Battlefield wants the same thing: the Disrupt Main Stage. Here’s how to get there and why the opportunity starts well before the main stage.

Jun 1, 2026

Here are the 5 Startup Battlefield finalists at TechCrunch Disrupt 2024

The time has finally come to announce the five finalists of the Startup Battlefield. It all started earlier this year when the TechCrunch editorial team selected 200 companies from thousands that applied. From there, the team then chose the 20 finalists who pitched this week onstage at TechCrunch Disrupt 2024 to investor judges and packed crowds. This year’s finalists follow in the footsteps of Startup Battlefield legends like Dropbox, Discord, Cloudflare and Mint on the Disrupt Stage. With ov

Oct 29, 2024

The 2026 Startup Battlefield 200 is here — see who made the cut

We're thrilled to unveil the 2026 — TechCrunch's annual, handpicked list of the 200 most promising early-stage startups from around the world. These founders rose to the top from thousands of applications spanning every industry and geography. Their reward? A coveted spot to exhibit at TechCrunch Disrupt 2026, taking place October 13–15 in San Francisco's Moscone West.

Aug 20, 2026